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Abstract 
Morbidly adherent placenta (MAP) can be associated with major maternal morbidity, 
and is increasing in frequency. Determination of optimal management has not yet 
been satisfactory. We identify problems with lack of uniformity and the need for 
standardized nomenclature for the diagnosis, treatment and research of MAP. We 
suggest potential solutions and identify areas of future work.  
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Overview 
Morbidly adherent placenta (MAP) occurs when the placenta fails to detach from the 
uterine wall due to abnormal implantation at the basal plate. This often leads to 
massive obstetric hemorrhage, and sequelae such as blood transfusion, multi-organ 
failure, need for morbid hysterectomy, and even death1.  Owing to the relative rarity 
of the condition, few high quality data are available regarding the optimal 
management.  However, it is increasing in frequency2, 3 and has become one of the 
most morbid obstetric disorders in developed nations2-7. This is likely due to a 
dramatic and persistent increase in the rate of cesarean delivery2-8. Determination of 
optimal management has been further hampered by a lack of standard nomenclature.  
Some definitions are clinical, others based on imaging, and still others based on 
histopathology. However, there is considerable variation among the definitions used 
among countries, regions, hospitals and even clinicians. Cases of MAP managed 
conservatively (without hysterectomy) are hard to define since there is no specimen to 
evaluate histologically. Consequently, it is difficult to compare results of studies and 
to improve care for women with MAP.         
 
This problem is highlighted by studies on the conservative management of MAP.  
Excellent outcomes have been reported after hysterotomy, leaving the placenta in-situ, 
partial removal of the placenta, or removal of the placenta with additional hemostatic 
suturing of the placental bed. However, none of these cases had confirmed placenta 
accreta spectrum based on histological examination.  Thus, it is difficult to counsel 
women regarding the true risks of conservative management of MAP. Many of these 
women had fewer traditional risk factors for MAP (such as multiple prior cesareans) 
than in other series. Accordingly, their outcomes may not be applicable to women 
with multiple prior cesarean sections and placenta previa. 
 
Accurate prenatal diagnosis is critical to reduce the risk of maternal morbidity and 
mortality. Indeed, several studies have reported that antenatal diagnosis of MAP leads 
to reduced blood loss and other complications9-11. In part, this is due to planned 
cesarean hysterectomy, delivery of the infant through a fundal hysterotomy and 
avoidance of the placenta.  In addition, it allows for planned delivery under optimal 
circumstances in a center of excellence skilled in the delivery of women with MAP12. 
Unfortunately, the ability to antenatally diagnose MAP is imperfect, in part due to a 
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lack of uniform nomenclature and significant overlap of ultrasound markers of MAP 
with normally implanted placentas.     
 
There are numerous reports on prenatal diagnosis of invasive placentation using 
ultrasound13. In fact, relatively high sensitivities and specificities have been described, 
albeit in high-risk cases and with full knowledge of clinical risk factors. 
Unfortunately, there is low consistency in the terminology used to describe the 
sonographic features of MAP.  In turn, this makes it difficult to compare studies of 
sonographically diagnosed MAP. In addition, there are substantial clinical 
implications since failure to diagnose MAP may lead to avoidable morbidity while 
false positive diagnoses may result in unnecessary hysterectomies and loss of fertility. 
Clearly there is a need for standardized nomenclature when it comes to the diagnosis, 
treatment and research of MAP.  
 
 
Issues with antenatal diagnosis of invasive placentation 
Ultrasound features of invasive placentation have been described and can be divided 
into the following groups: 
a. Direct visualization of placental tissue beyond the uterine cavity, such as a 
bulging mass in the urinary bladder. Although visualization of the placenta in 
the bladder cavity is strong evidence of abnormal placental invasion, this is a 
rare finding. Consequently, the sensitivity is low, but specificity is high. 
Overall, the prevalence of this sign in cases of confirmed invasive placentation 
is very low.   
b. Abnormalities of the placental-uterine interface. Using gray scale ultrasound, 
loss of the normal hypo-echoic retro-placental space has been described as a 
sign of MAP. This feature is however, operator and angle dependent, varies 
between an anterior or posterior placenta and is associated with a high false 
positive rate.  
c. Lower segment myometrial thickness. The myometrial thickness in the lower 
segment is measurable in millimeters. A study of 30 women with previous 
Caesarean delivery using both trans-abdominal and transvaginal ultrasound 
between 36 and 39 weeks of gestation, reported the thickness of the entire 
lower uterine segment to be 3.6 – 19.2 mm, and 1.0–9.7 mm, respectively. The 
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95% limits of agreement were 3.5 mm and 0.8 mm, respectively. This metric 
is poorly reproducible and subject to considerable variation14. The sign has 
been described in many cases without invasive placentation, and the observed 
specificity is low15.   
d. Color Doppler studies. Using color Doppler ultrasound, increased vascularity 
of the lower segment-urinary bladder interface has been described (Table 1). 
This is subjective since currently there are no quantitative indicators to 
measure such increased vascularity, rather there is the appearance of increased 
vascularity compared to normal controls. Location of the placenta in the lower 
uterine segment alone is enough to increase vascularity as compared to those 
with fundal placenta and with prior cesarean deliveries, increased vascularity 
and scarring is often seen in the lower uterine bladder interface in pregnancies 
without MAP. Indeed, ‘increased’ vascularity can be made to appear by 
changing the sensitivity of the ultrasound machine even in cases where 
placenta is not implanted in the lower uterine segment (Please see Figure 1).  
Almost all publications with placenta accreta examine only women with 
known risk factors such as low anterior placenta and previous Caesarean 
delivery. Therefore, selection bias may explain the ‘increased’ vascularity at 
the lower segment interface. It remains undetermined whether such ‘increased’ 
vascularity is a result of abnormal invasion versus low-anterior placental 
location and how this may be objectively measured.  Collins et al16 , using off-
line analysis of volumes obtained with 3-D power Doppler ultrasound, showed 
significantly increased area of vascular confluence in the maternal-fetal 
interface of placenta in women with MAP as compared to controls. This could 
be helpful to remove subjectivity in reporting increased vascularity associated 
with MAP. However, this technique is not readily available to clinicians, and 
independent validation is needed before it can be used clinically  
e. Abnormalities of the placental echo-structure: Presence of placental lacunae 
was an early described sign reported with MAP17-19. The pathophysiology is 
unclear but may result from placental tissue alterations resulting from long-
term exposure to pulsatile flow. The content of the lacunae has been described 
variably as having low velocity flow20, turbulent flow21, diffuse or focal 
flow22-24 or turbulent high velocity flow25 (Table 2). ‘Abnormal’ and 
‘confluent’ vessels have been described with invasive placentation, but no 
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definition is available of the normal range of appearances. Furthermore, 
location and size of placental lacunae have not been clearly defined in relation 
to the prediction of MAP. 
f. Parametrial invasion: Many series describe abnormal placental invasion 
anteriorly, presumably through a previous uterine scar. Lateral (parametrial) 
invasion of placental tissue has been demonstrated on MRI26. Insufficient 
healing of the uterine incision extending into the lateral wall, and implantation 
with subsequent invasive placentation extending into the parametrium is a 
plausible explanation for this phenomenon. The frequency of parametrial 
invasion was 18% (62/342) of all cases of invasive placentation in one 
series26.  
 
Problems with ascertainment of invasive placentation 
 
There are two main theoretical approaches to the definitive ascertainment of MAP. 
One is histopathological confirmation, and the other is based on surgical findings. 
Both are problematic for different reasons.   
 
Placental Histological Examination 
 
Most cases of MAP are due to placenta accreta spectrum, representing different 
grades of morbid placental attachment secondary to invasion of placental tissue deep 
into the myometrium beyond the normal utero-placental interface. Placenta accreta is 
histologically defined as placental attachment to the myometrium without intervening 
decidua. If there is deep myometrial invasion it is termed placenta increta and if 
invasion through myometrium into the serosa and beyond, even into surrounding 
structures such as the bladder, it is termed percreta.  The term placenta accreta 
spectrum also is often used in cases of clinically apparent morbidly adherent placenta. 
 
Placenta accreta is often simplistically defined as invasion of the myometrium with 
placental villi in contact with myometrial tissue. However, the main histological 
feature is the absence of normal decidua at the basal plate, and the detection of such 
findings is dependent on the mode of placental delivery and sampling issues.  In one 
study microscopic foci of myometrial tissue adherent to the basal plate with deficient 
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intervening decidua, consistent with a mild or focal form of placenta accreta, were 
described in 36 placentas, of which only four had a clinical diagnosis of placenta 
accreta, none requiring hysterectomy27. It was concluded that mild cases of placenta 
accreta are frequently associated with previous uterine operations and multiparity, and 
are clinically suspected only infrequently. Similar findings were also reported in 44 of 
457 (9.6%) preterm (birth < 32 weeks) placentas, with basal plate myometrial fibres 
present28 and in another study of 90 consecutive singleton placentas basal plate 
myometrial fibers were seen in 27/90 (30%)29. Only 9 of these 27 had clinical features 
suggestive of placenta accreta, such as postpartum hemorrhage, delayed third stage of 
labor, retained placenta, or need for manual removal. The high frequency of 
myometrial fibers were attributed to extensive sampling and it was suggested that 
myometrial fibers in the placental basal plate can confirm, but do not necessarily 
indicate clinical placenta accreta.  
Conversely, conservative surgery may leave residual adherent parts of the placenta in-
situ and therefore histopathological confirmation will not be possible. Moreover, the 
pathologist is more likely to seek invasive placentation if extirpative surgery has been 
performed whereas features of MAP may be missed if the pathologist only assesses a 
small number of routine placental sections. Furthermore, practice and expertise 
among pathologists varies considerably and there is no “standard” approach for 
assessment and diagnosis of MAP.  It is now generally agreed that histologically, the 
characteristic feature of invasive placentation is not only the close localization of villi 
and myometrium, but rather the histological lack of decidua between chorionic villi 
and myometrium, often with only fibrin intervening.  We are not aware of any blinded 
studies or indeed any studies which have examined the effects of sampling on false 
negatives in true cases. 
 
Clinical Diagnosis: 
 
Placental tissue may be seen at the site of the surgical scar on direct visualization25. It 
may be argued that the picture resembles the fetal surface of the placenta, whereas 
one expects to see the maternal surface. It is not always easy to tell where the placenta 
ends and the myometrium begins. A vascular lower segment in a case of anterior 
placenta previa may well be indistinguishable from ‘placenta in the scar’.  
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A diagnosis of MAP also is made when the placenta is adherent to the uterus and does 
not easily detach, however, again this is subjective, with no clear distinction between 
MAP and “retained placenta” in many cases. There are no objective criteria for the 
clinical diagnosis of MAP. The ultimate aim is prediction of major morbidity, whether 
or not invasive placentation is confirmed on histopathology or at surgery.  
 
Future directions 
 
Identification of at risk women: Several risk factors for invasive placentation have 
been described.  
There is accumulating evidence to suggest that a Caesarean scar pregnancy detected 
in the first trimester is a precursor of MAP 30-33. There is a lack of agreement 
regarding the most appropriate diagnostic criteria for Caesarean scar pregnancy34. 
However, a high proportion of Caesarean scar pregnancies result in morbidly adherent 
placenta in the absence of intervention 35-37. This is not inevitable though, as 
uncomplicated pregnancy and delivery has been reported following conservative 
management of Caesarean scar pregnancy34.  
In the second half of pregnancy, the most common and clinically important risk factor 
is the combination of placenta previa and previous lower segment Caesarean delivery. 
Uterine surgery such as myomectomy, curettage or endometrial resection/ablation 
also increases the risk, but it is often difficult to know the exact site of the previous 
injury, although reports of prenatal diagnosis of fundal placenta accreta have been 
published. In such cases it is possible to deliver the infant without disturbing the 
placenta and deal with the placenta later. Hemostasis is likely to be easier, and 
parametrial structures are not directly at risk. In a series of 187 women with placenta 
previa and previous uterine surgery, 46 (24.6%) had previous myomectomy and 23 
(12.3%) had prior curettage, but none had confirmed MAP25. The greatest yield of 
risk factors seems to be women with presence of placenta in the anterior lower 
segment with previous lower segment scar.  
 
Agreement on standard operating procedure for evaluation of women: It is 
unclear if women should be examined with empty, partly filled or full urinary bladder, 
and if trans-abdominal or transvaginal scan should be used. Prospective studies should 
be directed to collect data by examining women abdominally as well as using TV 
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scan, and with and without bladder filling in all cases, also assessing possible 
parametrial extension on ultrasound. The most appropriate gestational age at which 
assessment should be performed is also unclear.  
 
Use of MRI: The MRI literature for antenatal detection of MAP is biased, because 
MRI is not a screening method. Moreover, the technique can only be as good as the 
individuals interpreting the images. It has been suggested that MRI is particularly 
valuable for parametrial invasion26. Parametrial invasion is not commonly reported by 
other authors though. When the reported diagnostic performance of ultrasound so 
good with high sensitivity and specificity, it is debatable if MRI can add substantially 
to this. Use of safe contrasts may improve the diagnostic performance of MRI in 
future.  
 
Agreement on how to ascertain clinically relevant MAP: Agreement of what 
constitutes clinically significant invasive placentation is required. The placenta should 
either be anterior and low lying (placental edge to internal os distance of 2 cm or less) 
or complete posterior previa with anterior extension. In those cases where a fundal 
incision is made, the placenta must not spontaneously detach after the delivery of the 
baby. Part of the placenta must remain attached to the uterine wall even if the rest of 
the placenta can be peeled off. Protocols for sampling have been published38, 39, and 
include 2-4 full thickness ‘random’ sections, each of which should have a variable 
amount of basal / maternal material, including decidua and/or myometrium. As 
described above, presence of histopathological features without complications such as 
bleeding is of little clinical significance. Formal blinded assessment by 
histopathologists to ascertain the degree of inter-observer agreement of MAP is 
required, compared to an agreed clinico-pathological gold-standard for the diagnosis 
of clinically relevant MAP.  
 
Agreement on terminology of description: Consensus is required regarding the 
definition of clinical and imaging features such as ‘echo poor areas’; and lacunae, 
number and location of lacunae, as distinguished from other ultrasonographic features 
such as ‘lakes’ or ‘fall-out areas’, Doppler interrogation of the contents of lacunae and 
documentation of the type of flow and storage of 3-D volumes for blinded off-line 
assessment is required.  The lower segment-bladder boundary examined with grey 
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scale and colour flow mapping should be assessed. All features should be assessed 
blindly. Significant inter-observer variability in the diagnosis of invasive placentation 
has been reported when examiners were blinded from clinical data40. 
 
Towards these ends, the European group on invasive placentation is sharing 
experiences of women with suspected MAP as a first step towards developing 
consensus for the diagnosis and management of this condition. Recently, standardized 
ultrasound descriptors41 and reporting42 for abnormally invasive placenta have been 
suggested based on consensus amongst experts, with a focus on unambiguous 
definition in a move towards universally agreed terminology. However, subjectivity 
still remains with several features such as ’increased’ vascularity and 'irregularity' of 
the bladder interface, which remain otherwise undefined. Assessment of the predictive 
accuracy of these signs will remain problematic without agreement on what 
constitutes a clinically relevant MAP. We suggest a consistent clinical definition of 
abnormal placental invasion, imaging terminology and pathological criteria to this end 
(Table 3). The terminology deliberately avoids the term ‘accreta’. As already 
mentioned, the aim is to identify disorders associated with major maternal 
morbidity/mortality.  
 
Whilst definitive antenatal diagnosis may not be possible, by developing scoring 
systems and assigning weight to individual signs depending on their positive 
likelihood ratios, improved detection and management should be possible. Such future 
developments should be on the basis of robust data rather than logic, reasoning or 
consensus of ‘experts’. 
Acknowledgements: The authors report no conflict of interest.  
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Legends to figures 
Figure 1 – Colour flow mapping in a pregnancy where the placental attachment is in 
the posterior uterine wall in the upper uterine segment. Alteration of the equipment 
setting can result in a subjective appearance of increased vascularity.  
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Table 1 Description of increased vascularity 
Author Year Description 
Calì25 2013 Hypervascularity/Abnormal vascularity of serosa–bladder 
interface, Hypervascularity of uterine serosa-bladder 
interface (coronal view), Irregular intraplacental 
vascularization with tortuous confluent vessels across 
placental width (lateral view) 
Peker43 2013 Hypervascularity/Abnormal vascularity of serosa–bladder 
interface 
Mansour44 2011 Hypervascularity/Abnormal vascularity of serosa–bladder 
interface 
El 
Beherry21 
2010 Vessels crossing the interface disruption site 
Shih22 2009 Hypervascularity/Abnormal vascularity of serosa–bladder 
interface, Numerous coherent vessels involving the whole 
uterine serosa–bladder junction (basal view), 
Hypervascularity (lateral view), Inseparable cotyledonal and 
intervillous circulations (lateral view) 
Miura22 2008 Hypervascularity/Abnormal vascularity of serosa–bladder 
interface 
Wong45 2008 Vessels extending from the placenta to the bladder, Vessels 
crossing the interface disruption site, Vessels extending from 
the placenta to the bladder, Increased sub-placental 
vascularity, Vessels bridging the placenta and the uterine 
margin 
Japaraj46 2007 Hypervascularity/Abnormal vascularity of serosa–bladder 
interface, Dilated peripheral subplacental vascular channels 
with pulsatile venous type flow over the cervix,  
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Table 2. Description of placental lacunae 
 
 
 
  
Author Year Large linear  
lacunae with low 
velocities CD flow 
Diffuse or 
focal lacunar 
flow pattern 
Vascular lakes 
with turbulent 
flow 
Vascular lakes with 
turbulent flow with high 
velocity (PSV > 15 cm/s) 
Dilated vascular 
channels with 
diffuse lacunar flow 
Calì25 2013    X  
Chalubinski47 2013   X   
Peker43 2013    X  
El Behery43 2010   X   
Shih22 2009  X  X  
Wong45 2008  X    
Japaraj46 2007     X 
Chou23 2000  X  X  
Twickler20 2000 X     
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Table 3 Suggested terminology of description 
 
Imaging definition 
 
 
2 D gray scale Presence of bulk of the placenta in the lower uterine segment 
Presence of placental lacunae (multiple) 
Bladder wall interruption 
Interruption of the bladder wall 
Placental bulge/exophytic mass 
Colour Doppler/Power angio 
 
Bridging vessels 
Placental lacunae with/without flow 
3-D ultrasound Signs as in 2-D ultrasound 
Clinical definition Placenta that does not separate at all, or separates only partly following the delivery of the 
baby. 
Attempt at removal of the placenta leads to brisk hemorrhage.  
Placenta seen to be permeating the full thickness of the uterine wall or infiltrating into the 
urinary bladder or parametrium.  
Pathology definition/criteria Histological lack of decidua between chorionic villi and myometrium, often with only fibrin 
intervening.  
Close localisation of villi and myometrium can be an artifact and not sufficient for diagnosis.   
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